A groundbreaking HIV-prevention drug, lenacapavir, is set to revolutionize the fight against HIV/AIDS.
A partnership between Unitaid, the Gates Foundation, and Indian pharmaceutical companies, generic versions of this injectable drug will be available for just $40 per year in over 120 low- and middle-income countries starting in 2027.
Lenacapavir has shown remarkable effectiveness in preventing HIV transmission, with a success rate of over 99.9%.
In contrast to the generic version's price, the branded version of lenacapavir, Yeztugo, costs approximately $28,000 annually in the United States.
The generic versions will initially be manufactured in India, with potential for future regional production.
Unitaid, the Gates Foundation, and the Clinton Health Access Initiative are collaborating to make this initiative a success, with Dr. Reddy's Laboratories and Hetero Labs among the pharmaceutical companies involved.
This agreement aims to deliver the drug to millions of people in need, particularly in low-income countries where HIV/AIDS remains a significant public health challenge.
Experts estimate that long-term demand for lenacapavir could reach 10 million people or more, highlighting the importance of affordable generics.
Despite this progress, concerns remain about upper-middle-income countries being excluded from the generics agreement, potentially limiting access in regions like Latin America .
Click to signup for FREE news updates, latest information and hottest gists everydayAdvertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com